Brett A. Pletcher net worth and biography

Brett Pletcher Biography and Net Worth

Brett Pletcher leads a group at Gilead that includes the government affairs and policy, public affairs, and legal organizations. In his role, he oversees our work to shape health policy and communicate the company’s perspective across external audiences. As General Counsel, he is also responsible for all of the company’s legal functions, including intellectual property, litigation and compliance efforts associated with the promotion of our products.

Before joining Gilead in 2005, Brett was a partner in the law firm of Gunderson Dettmer, LLP, where he provided corporate and securities services to emerging growth public and private companies as well as venture capital investors

Brett received his bachelor’s degree in economics and political science from the University of California, Riverside and earned his law degree from the University of California, Berkeley’s Boalt Hall School of Law.

He is a member of the California State Bar and a former member of the Nasdaq Listing and Hearing Review Council, and currently serves on the Advisory Board for the East Bay Community Law Center.

What is Brett A. Pletcher's net worth?: The estimated net worth of Brett A. Pletcher is at least $1.96 million as of March 11th, 2021. Mr. Pletcher owns 29,166 shares of Gilead Sciences stock worth more than $1,956,455 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Pletcher may own. Learn More about Brett A. Pletcher's net worth.
How do I contact Brett A. Pletcher?: The corporate mailing address for Mr. Pletcher and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Brett A. Pletcher's contact information.
Has Brett A. Pletcher been buying or selling shares of Gilead Sciences?: Brett A. Pletcher has not been actively trading shares of Gilead Sciences during the last ninety days. Most recently, Brett A. Pletcher sold 3,634 shares of the business's stock in a transaction on Friday, March 11th. The shares were sold at an average price of $58.24, for a transaction totalling $211,644.16. Learn More on Brett A. Pletcher's trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 30,228 shares worth more than $2,453,404.15. The most recent insider tranaction occured on April, 1st when insider Merdad Parsey sold 2,000 shares worth more than $145,920.00. Insiders at Gilead Sciences own 0.3% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 4/1/2024.

Brett A. Pletcher Insider Trading History at Gilead Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2022	Sell	3,634	$58.24	$211,644.16
2/9/2022	Sell	1,691	$63.89	$108,037.99
2/1/2022	Sell	14,061	$68.54	$963,740.94
3/11/2021	Sell	1,486	$63.36	$94,152.96	29,166
2/10/2021	Sell	1,975	$67.41	$133,134.75	28,832
5/5/2020	Sell	13,210	$79.23	$1,046,628.30	27,204
3/10/2020	Sell	2,950	$75.55	$222,872.50	17,594
3/2/2020	Sell	10,441	$70.88	$740,058.08	25,085
2/10/2020	Sell	2,950	$69.32	$204,494.00	27,640
2/6/2020	Sell	5,000	$68.18	$340,900.00	29,690
1/3/2020	Sell	2,950	$64.63	$190,658.50	20,014
12/3/2019	Sell	5,900	$65.77	$388,043.00	22,964
11/25/2019	Sell	15,000	$66.85	$1,002,750.00	32,064
11/19/2019	Sell	10,000	$64.91	$649,100.00	17,064
11/5/2019	Sell	2,095	$66.06	$138,395.70	17,826
11/1/2019	Sell	4,000	$64.52	$258,080.00	23,921
10/28/2019	Sell	5,677	$63.31	$359,410.87	21,521
8/19/2019	Sell	608	$64.35	$39,124.80	27,198
7/23/2019	Sell	7,200	$65.07	$468,504.00	34,398
6/18/2019	Sell	5,816	$68.75	$399,850.00	27,198

Brett A. Pletcher Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $65.30

$65.26

$67.90

50 Day Range

MA: $71.56

$66.16

$75.94

2 Week Range

Now: $65.30

$65.26

$87.86

Volume

6,080,275 shs

Average Volume

7,293,857 shs

Market Capitalization

$81.30 billion

P/E Ratio

14.51

Dividend Yield

4.59%

Beta

0.19

The "Smart Money" Is Ready for May 1st Are You?

From Stansberry Research | Ad

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…